MedTrace Logo

Dissecting the Pathways of Therapy Resistance in Early Breast Cancer

NCT04995575 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2024-02-22

No results posted yet for this study

Summary

Within the 1st step MINDACT patients who have already relapsed will be asked to participate. For these patients a biopsy of the metastasis should have been taken. A molecular analysis of the stored primary tumor sample and of the metastatic sample, using new technologies, will be performed, and the characteristics of both samples will be compared.

Within the 2nd step a prospective collection of the metastasis samples will be implemented and analysis of biological material from relapsing MINDACT patients is foreseen.

This process will provide insights on the biology of breast cancer and allow us to better understand mechanisms of resistance to therapies, contributing to overcoming this important problem.

Conditions

Interventions

PROCEDURE

collection of the biopsy, blood samples

for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals. For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2022-05-09
Completion
2023-10-23

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04995575 on ClinicalTrials.gov